AU2001253158A1 - Methods of investigating, diagnosing, and treating amyloidosis - Google Patents

Methods of investigating, diagnosing, and treating amyloidosis

Info

Publication number
AU2001253158A1
AU2001253158A1 AU2001253158A AU5315801A AU2001253158A1 AU 2001253158 A1 AU2001253158 A1 AU 2001253158A1 AU 2001253158 A AU2001253158 A AU 2001253158A AU 5315801 A AU5315801 A AU 5315801A AU 2001253158 A1 AU2001253158 A1 AU 2001253158A1
Authority
AU
Australia
Prior art keywords
investigating
diagnosing
methods
treating amyloidosis
amyloidosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253158A
Inventor
Rudi Hrncic
Maria Schell
Alan Solomon
Jonathan Wall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Original Assignee
University of Tennessee Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tennessee Research Foundation filed Critical University of Tennessee Research Foundation
Publication of AU2001253158A1 publication Critical patent/AU2001253158A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001253158A 2000-04-05 2001-04-05 Methods of investigating, diagnosing, and treating amyloidosis Abandoned AU2001253158A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19468400P 2000-04-05 2000-04-05
US60/194,684 2000-04-05
PCT/US2001/011043 WO2001077167A2 (en) 2000-04-05 2001-04-05 Methods of investigating, diagnosing, and treating amyloidosis

Publications (1)

Publication Number Publication Date
AU2001253158A1 true AU2001253158A1 (en) 2001-10-23

Family

ID=22718526

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253158A Abandoned AU2001253158A1 (en) 2000-04-05 2001-04-05 Methods of investigating, diagnosing, and treating amyloidosis

Country Status (5)

Country Link
US (1) US7485616B2 (en)
EP (1) EP1353944A2 (en)
AU (1) AU2001253158A1 (en)
CA (1) CA2404237C (en)
WO (1) WO2001077167A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7485616B2 (en) * 2000-04-05 2009-02-03 University Of Tennessee Research Foundation Methods of investigating, diagnosing, and treating amyloidosis
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2006519762A (en) * 2002-10-09 2006-08-31 ライナット ニューロサイエンス コーポレイション Methods for treating Alzheimer's disease using antibodies against amyloid β peptide and compositions thereof
PE20050627A1 (en) 2003-05-30 2005-08-10 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
WO2005059100A2 (en) * 2003-12-12 2005-06-30 New York University Methods and compositions relating to cystatin c
AP2007003890A0 (en) * 2004-07-30 2007-02-28 Rinat Neuroscience Corp Antibodies directed against amy-loid-beta peptide and methods using same
JP2008523815A (en) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド Humanized amyloid beta antibody for use in improving cognition
PE20061323A1 (en) 2005-04-29 2007-02-09 Rinat Neuroscience Corp ANTIBODIES TARGETED AGAINST AMYLOID BETA PEPTIDE AND METHODS USING THEM
WO2007047436A2 (en) * 2005-10-17 2007-04-26 Mayo Foundation For Medical Education And Research Methods and materials for producing a generic anti-amyloid immune response in mammals
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2182983T3 (en) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap TREATMENT OF AMYLOIDOGENIC DISEASES WITH HUMANIZED ANTI-ABETA ANTIBODIES
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
ES2544679T3 (en) 2007-12-28 2015-09-02 Prothena Biosciences Limited Treatment and prophylaxis of amyloidosis
FI20085340L (en) * 2008-04-22 2009-10-23 Medixine Oy Health screening and a method for implementing the health screening
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9683017B2 (en) 2014-07-17 2017-06-20 University Tennessee Research Foundation Inhibitory peptides of viral infection
WO2016032949A1 (en) 2014-08-26 2016-03-03 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2017184973A1 (en) * 2016-04-22 2017-10-26 University Of Tennessee Research Foundation Identifying amyloidogenic proteins & amyloidogenic risk
EP3691447A4 (en) 2017-10-06 2021-08-11 Prothena Biosciences Limited Anti-transthyretin antibodies
EA202091130A1 (en) 2017-11-29 2020-08-28 Протена Биосайенсис Лимитед LYOPHILIZED PREPARATION OF MONOCLONAL ANTIBODY TO TRANSTYRETIN
WO2021168156A1 (en) * 2020-02-20 2021-08-26 Prothena Biosciences Limited Monitoring transthyretin amyloidosis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3521684A1 (en) * 1985-06-18 1986-12-18 Dr. Müller-Lierheim KG, Biologische Laboratorien, 8033 Planegg METHOD FOR COATING POLYMERS
EP0526511B1 (en) 1990-04-27 1997-05-28 MCMICHAEL, John Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein
JP2988635B2 (en) * 1990-09-18 1999-12-13 塩野義製薬株式会社 Monoclonal antibody against human IgE
AU4382193A (en) * 1992-05-19 1993-12-13 Xoma Corporation BPI-immunoglobulin fusion proteins
US5750106A (en) * 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
EP0760676B1 (en) * 1994-05-25 2001-07-11 McMICHAEL, John Materials and methods for treatment of plaquing diseases
US5786180A (en) * 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
WO1999060024A1 (en) 1998-05-21 1999-11-25 The University Of Tennessee Research Corporation Methods for amyloid removal using anti-amyloid antibodies
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7485616B2 (en) * 2000-04-05 2009-02-03 University Of Tennessee Research Foundation Methods of investigating, diagnosing, and treating amyloidosis

Also Published As

Publication number Publication date
US7485616B2 (en) 2009-02-03
CA2404237A1 (en) 2001-10-18
CA2404237C (en) 2010-01-26
EP1353944A2 (en) 2003-10-22
US20020019335A1 (en) 2002-02-14
WO2001077167A3 (en) 2003-08-28
WO2001077167A2 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
AU2001253158A1 (en) Methods of investigating, diagnosing, and treating amyloidosis
AU2001252973A1 (en) Biosensor and related method
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AU2002215125A1 (en) Well treatment method
AU2001284858A1 (en) Improved suturing apparatus and method
AU2002213199A1 (en) Self-sampling brush and method for use
AU2001245928A1 (en) Electrolyzer and method of using the same
AU2001264771A1 (en) Well reference apparatus and method
AU2001253065A1 (en) Compositions and methods for treating hair loss using oximyl- and hydroxylamino-prostaglandins
AU2002357801A1 (en) Unitary trifunctional door manager and method
AU2002237774A1 (en) Latch apparatus and method
AU2001269947A1 (en) Noise reduction method and apparatus
AU6136499A (en) Injector, methods for using injector, and kit
AU2271400A (en) Composition, kit, method and device for hair treatment
AU2001243394A1 (en) Compounds and methods
AU2001289123A1 (en) Compounds and methods for diagnosing and treating amyloid-related conditions
AU2002324895A1 (en) Cosmetic kit and method
AU3204899A (en) Hair treatment composition and method
AU2002227247A1 (en) Biofilm therapy process and elements
AU2001218024A1 (en) Methods for treating and preventing alopecia
AU2001278951A1 (en) Compounds and methods
AU2931001A (en) Nitrided elements and method of making same
AU2002237253A1 (en) Biosensor and method of producing the same
AU5974999A (en) Hair treatment composition, method and use
AU4677601A (en) Keyless encryption system and method